TY - JOUR
T1 - Development of engineered t cells expressing a chimeric CD16-CD3ζ Receptor to improve the clinical efficacy of mogamulizumab therapy against adult T-Cell leukemia
AU - Tanaka, Hiroki
AU - Fujiwara, Hiroshi
AU - Ochi, Fumihiro
AU - Tanimoto, Kazushi
AU - Casey, Nicholas
AU - Okamoto, Sachiko
AU - Mineno, Junichi
AU - Kuzushima, Kiyotaka
AU - Shiku, Hiroshi
AU - Sugiyama, Takashi
AU - Barrett, A. John
AU - Yasukawa, Masaki
N1 - Publisher Copyright:
©2016 American Association for Cancer Research.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Purpose: Mogamulizumab (Mog), a humanized anti-CC chemokine receptor 4 (CCR4) mAb that mediates antibodydependent cellular cytotoxicity (ADCC) using FcγR IIIa (CD16)-expressing effector cells, has recently been approved for treatment of CCR4-positive adult T-cell leukemia (ATL) in Japan. However, Mog failure has sometimes been observed in patients who have accompanying chemotherapy-associated lymphocytopenia. In this study, we examined whether adoptive transfer of artificial ADCC effector cells combined with Mog would overcome this drawback. Experimental Design: We lentivirally gene-modified peripheral blood T cells from healthy volunteers and ATL patients expressing the affinity-increased chimeric CD16-CD3z receptor (cCD16ζ-T cells). Subsequently, we examined the ADCC effect mediated by those cCD16ζ-T cells in the presence of Mog against ATL tumor cells both in vitro and in vivo Results: cCD16ζ-T cells derived from healthy donors killed in vitro Mog-opsonized ATL cell line cells (n= 7) and primary ATL cells (n = 4) depending on both the number of effector cells and the dose of the antibody. cCD16ζ-T cells generated from ATL patients (n= 3) also exerted cytocidal activity in vitro against Mogopsonized autologous ATL cells. Using both intravenously disseminated model (n= 5) and subcutaneously inoculated model (n= 4), coadministration of Mog and human cCD16ζ-T cells successfully suppressed tumor growth in xenografted immunodeficient mice, and significantly prolonged their survival (P < 0.01 and P= 0.02, respectively). Conclusions: These data strongly suggest clinical feasibility of the novel combined adoptive immunotherapy using cCD16ζ-T cells and Mog for treatment of aggressive ATL, particularly in patients who are ineligible for allogeneic hematopoietic stem cell transplantation.
AB - Purpose: Mogamulizumab (Mog), a humanized anti-CC chemokine receptor 4 (CCR4) mAb that mediates antibodydependent cellular cytotoxicity (ADCC) using FcγR IIIa (CD16)-expressing effector cells, has recently been approved for treatment of CCR4-positive adult T-cell leukemia (ATL) in Japan. However, Mog failure has sometimes been observed in patients who have accompanying chemotherapy-associated lymphocytopenia. In this study, we examined whether adoptive transfer of artificial ADCC effector cells combined with Mog would overcome this drawback. Experimental Design: We lentivirally gene-modified peripheral blood T cells from healthy volunteers and ATL patients expressing the affinity-increased chimeric CD16-CD3z receptor (cCD16ζ-T cells). Subsequently, we examined the ADCC effect mediated by those cCD16ζ-T cells in the presence of Mog against ATL tumor cells both in vitro and in vivo Results: cCD16ζ-T cells derived from healthy donors killed in vitro Mog-opsonized ATL cell line cells (n= 7) and primary ATL cells (n = 4) depending on both the number of effector cells and the dose of the antibody. cCD16ζ-T cells generated from ATL patients (n= 3) also exerted cytocidal activity in vitro against Mogopsonized autologous ATL cells. Using both intravenously disseminated model (n= 5) and subcutaneously inoculated model (n= 4), coadministration of Mog and human cCD16ζ-T cells successfully suppressed tumor growth in xenografted immunodeficient mice, and significantly prolonged their survival (P < 0.01 and P= 0.02, respectively). Conclusions: These data strongly suggest clinical feasibility of the novel combined adoptive immunotherapy using cCD16ζ-T cells and Mog for treatment of aggressive ATL, particularly in patients who are ineligible for allogeneic hematopoietic stem cell transplantation.
UR - http://www.scopus.com/inward/record.url?scp=84988568745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988568745&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-2714
DO - 10.1158/1078-0432.CCR-15-2714
M3 - Article
AN - SCOPUS:84988568745
VL - 22
SP - 4405
EP - 4416
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 17
ER -